

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PATENT


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date indicated below with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Ariel Fletcher

Ariel Fletcher



11/27/2002

Date of Deposit.

Applicant: Brooks, et al.)

Serial No.: 09/081,522)

Filed: May 19, 1998)

Title: INHIBITION OF ANGIOGENESIS)
IN DISEASE STATES WITH AN)
ANTI- $\alpha_v\beta_3$ MONOCLONAL)
ANTIBODY (AS AMENDED))

Group Art Unit: 1644

Examiner: P. Gambel

Our Ref.: TSRI 419.0 Con 1

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In recognition of their continuing duty to disclose pursuant to 37 CFR §1.56, Applicants hereby submit the present Supplemental Information Disclosure Statement and accompanying PTO Form 1449 in compliance therewith.

Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Supplemental

Information Disclosure Statement may be material pursuant to 37 CFR §1.56, it shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability unless specifically designated as such.

Applicants are filing the present statement pursuant to 37 CFR §1.97(c). The statement is accompanied by a check in the amount of \$180.00 as payment of the fee set forth in 37 CFR §1.17(p) in accordance with 37 CFR §1.97(c)(2).

Also, in accordance with 37 CFR §1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR §1.56 exists.

Respectfully submitted,

11/27/02
Date

Emily Holmes
Emily Holmes, Reg. No. 40,652

THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, CA 92037
(858) 784-2937

1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.
TSRI 419.0 C1

SERIAL NO.
09/081,522

APPLICANT
Brooks, et al.


FILING DATE
05/19/98

GROUP
1644

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE



FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

1	Christofanilli, et al., "Angiogenesis Modulation In Cancer Research: Novel Clinical Approaches", <u>Nature Reviews</u> 1: 415-426 (2002)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.